DELRAY BEACH, Fla., June 17, 2013 (GLOBE NEWSWIRE) — PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), a developer of biological detection and diagnostics solutions, today announced its Chief Executive Officer, William J. Caragol, is featured in an interview on StockTradersTalk.com to discuss the Company’s M-BAND (Microfluidic Bio-agent Autonomous Networked Detector) and Firefly Dx system ("Firefly") technologies. The interview can be heard through this link.
About M-BAND and Firefly
PositiveID’s M-BAND system, developed under contract with the U.S. Department of Homeland Security Science and Technology directorate, is a bio-aerosol monitor with fully integrated systems for sample collection, processing and detection modules that continuously analyze air samples for the detection of bacteria, viruses, and toxins. Results are reported via a secure wireless network in real time to give an accurate and up-to-date status for fielded instruments. Firefly takes the Company’s patented molecular diagnostic technology underlying the M-BAND system, and implements it in a handheld device that can be used anywhere, anytime for rapid biological testing. Firefly is being designed as a portable, point-of-need molecular diagnostic system to provide test results from sample input through reporting of results in 15 to 30 minutes depending on the type of test performed.
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America’s homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. For more information on PositiveID, please visit http://www.PositiveIDCorp.com.
Statements about PositiveID’s future expectations, including, without limitation, the likelihood that results from M-BAND are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments; the likelihood that Firefly takes the Company’s patented molecular diagnostic technology underlying the M-BAND system, and implements it in a handheld device that can be used anywhere, anytime for rapid biological testing; the likelihood that Firefly is being designed as a portable, point-of-need molecular diagnostic system to provide test results from sample input through reporting of results in 15 to 30 minutes depending on the type of test performed; and all statements in this press release constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the biological detection and diagnostic sectors; the Company’s ability to attract the research and development capital to complete the development of Firefly; as well as other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on April 16, 2013 under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Stock Traders Talk
Peter J. Nicosia – Director of Marketing